LLY

1,008.06

+2%↑

JNJ

242.47

+0.89%↑

ABBV

227.83

-0.92%↓

NVS

162.82

+1.92%↑

AZN

194.72

+0.18%↑

LLY

1,008.06

+2%↑

JNJ

242.47

+0.89%↑

ABBV

227.83

-0.92%↓

NVS

162.82

+1.92%↑

AZN

194.72

+0.18%↑

LLY

1,008.06

+2%↑

JNJ

242.47

+0.89%↑

ABBV

227.83

-0.92%↓

NVS

162.82

+1.92%↑

AZN

194.72

+0.18%↑

LLY

1,008.06

+2%↑

JNJ

242.47

+0.89%↑

ABBV

227.83

-0.92%↓

NVS

162.82

+1.92%↑

AZN

194.72

+0.18%↑

LLY

1,008.06

+2%↑

JNJ

242.47

+0.89%↑

ABBV

227.83

-0.92%↓

NVS

162.82

+1.92%↑

AZN

194.72

+0.18%↑

Home・Akciju saraksts・CytomX Therapeutics Inc

CytomX Therapeutics Inc

Slēgts

SektorsVeselības aprūpe

5.04 7.69

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

4.52

Max

5.04

Galvenie mērījumi
By Trading Economics
Ienākumi	-14M -14M
Pārdošana	-13M 6M
P/E Sektora vidējais	17.8 66.845
Peļņas marža	-238.621
Darbinieki	119
EBITDA	-13M -14M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt (spēcīgs)
Prognoze 12 mēnešiem	+102.99% upside

Dividendes
By Dow Jones
Nākamie ieņēmumi	2026. g. 16. marts

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	257M 905M
Iepriekšējā atvēršanas cena	-2.65
Iepriekšējā slēgšanas cena	5.04

Tehniskais rādītājs

By Trading Central

Pārliecība

Strong Bullish Evidence

0.7658 / N/A Atbalsts un pretestība

CytomX Therapeutics Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 9. marts 18:13 UTC

Iegādes, apvienošanās, pārņemšana

Shell to Sell Jiffy Lube to Monomoy in $1.3 Billion Deal -- Update

2026. g. 9. marts 17:20 UTC

Galvenie ziņu notikumi

U.S. Ag Industry Calls for Government Intervention on Fertilizer Prices

2026. g. 9. marts 17:15 UTC

Iegādes, apvienošanās, pārņemšana

Shell to Sell Jiffy Lube and Premium Velocity to Monomoy for $1.3 Billion

2026. g. 10. marts 00:00 UTC

Galvenie ziņu notikumi

Why Iranian Regime Change Would Transform Global Energy Markets -- WSJ

2026. g. 9. marts 23:52 UTC

Tirgus saruna

Gold Steady; May Be Supported by Dollar's Weakness -- Market Talk

2026. g. 9. marts 23:50 UTC

Tirgus saruna

Nikkei May Rise as Fears About Higher Energy Prices Ease -- Market Talk

2026. g. 9. marts 23:50 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2026. g. 9. marts 23:46 UTC

Tirgus saruna

Galvenie ziņu notikumi

Correction to Crude Prices Market Talk on March 9

2026. g. 9. marts 23:42 UTC

Tirgus saruna

Galvenie ziņu notikumi

Oil Futures Fall Amid Developments That Could Help Supply -- Market Talk

2026. g. 9. marts 23:08 UTC

Galvenie ziņu notikumi

Front-Month WTI Futures Drop 7.9% to $87.29/bbl, ICE Data Show

2026. g. 9. marts 23:07 UTC

Galvenie ziņu notikumi

Front-Month WTI Futures Fall After Trump Says Iran War Will Be Over 'Very Soon'

2026. g. 9. marts 21:29 UTC

Iegādes, apvienošanās, pārņemšana

Fortescue Now Fully Owns Peru's Canariaco Copper Project

2026. g. 9. marts 21:28 UTC

Iegādes, apvienošanās, pārņemšana

Fortescue Completes Acquisition of Remaining Alta Copper Shares

2026. g. 9. marts 20:50 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2026. g. 9. marts 20:50 UTC

Tirgus saruna

Financial Services Roundup: Market Talk

2026. g. 9. marts 20:47 UTC

Galvenie ziņu notikumi

The 24 Hours When Oil Markets Went Wild -- WSJ

2026. g. 9. marts 20:33 UTC

Galvenie ziņu notikumi

Stock Market Today: Oil Slips, Stocks Bounce on Trump War-Progress Comments Headline -- WSJ

2026. g. 9. marts 20:14 UTC

Tirgus saruna

Galvenie ziņu notikumi

Oil Moves Lower As Trump Says War Could End Soon -- Market Talk

2026. g. 9. marts 19:33 UTC

Galvenie ziņu notikumi

High Oil Prices Could Crimp Convenience Store Margins -- Barrons.com

2026. g. 9. marts 19:17 UTC

Tirgus saruna

Galvenie ziņu notikumi

Prospect of Added Supply From Oil Reserves Ease Inflation Fears -- Market Talk

2026. g. 9. marts 19:14 UTC

Tirgus saruna

Oil Settles Off Highs As G7 Discusses Tapping Reserves -- Market Talk

2026. g. 9. marts 19:00 UTC

Tirgus saruna

U.S. Natural Gas Futures Settle Lower -- Market Talk

2026. g. 9. marts 18:23 UTC

Tirgus saruna

Galvenie ziņu notikumi

BofA Drops Canada Rate-Cut Call on Higher Oil Prices -- Market Talk

2026. g. 9. marts 17:58 UTC

Iegādes, apvienošanās, pārņemšana

Shell to Sell Jiffy Lube to Monomoy in $1.3B Deal -- Update

2026. g. 9. marts 17:57 UTC

Iegādes, apvienošanās, pārņemšana

Activist Investors Target Food Companies as Growth Slows. Lamb Weston Is the Latest. -- Barrons.com

2026. g. 9. marts 17:41 UTC

Galvenie ziņu notikumi

U.S. and Western Allies Turn to Reserves to Counteract Gulf Oil Crisis -- WSJ

2026. g. 9. marts 17:41 UTC

Tirgus saruna

Galvenie ziņu notikumi

Reports of Saudi Production Shut-Ins Keep Bid in Crude -- Market Talk

2026. g. 9. marts 17:08 UTC

Tirgus saruna

Canada Rate Outlook Shifts From Long Pause to Late 2026 Hike -- Market Talk

2026. g. 9. marts 17:04 UTC

Tirgus saruna

Galvenie ziņu notikumi

Global Forex and Fixed Income Roundup: Market Talk

2026. g. 9. marts 17:04 UTC

Tirgus saruna

Galvenie ziņu notikumi

Treasury Yields, Dollar Off Highs as G7 Tackles Oil Shock -- Market Talk

Salīdzinājums

Cenas izmaiņa

CytomX Therapeutics Inc Prognoze

Cenas mērķis

By TipRanks

102.99% augšup

Prognoze 12 mēnešiem

Vidējais 9.5 USD 102.99%

Augstākais 10 USD

Zemākais 7 USD

Pamatojoties uz 6 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi CytomX Therapeutics Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

6 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 6 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam CytomX Therapeutics Inc — pēdējo 3 mēnešu laikā.

Tehniskais rādītājs

By Trading Central

0.7658 / N/AAtbalsts un pretestība

Bullish events outweigh bearish events.

All events are bullish.

Recent bullish events outweigh bearish events.

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par CytomX Therapeutics Inc

CytomX Therapeutics, Inc., an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna; and clinical trial collaboration and supply agreement with Merck for the evaluation of CX-801 in combination with anti-PD-1 therapy, KEYTRUDA (pembrolizumab). CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.